The Basel-based venture capital firm BioMedPartners has raised CHF 75 million in the first closing of their fund BioMedInvest III, a healthcare venture capital fund that invests in private early-to-mid-stage companies.
BioMedPartners announced that the fund targets companies in Switzerland, Germany and neighbouring countries of the European Union. Among its investors are the European Investment Fund and the Berner Kantonalbank, Markus Hosang, general partner at BioMedPartners, said in a statement.
With its first closing, the fund will start to invest immediately in healthcare companies. Final closing is foreseen for early 2018 with a target size of CHF 120 million to CHF 150 million. BioMedInvest III intends to invest in 12 to 16 private companies and will support them not only by providing funds but also with expertise.
The BioMedPartners team includes venture capitalist specialists as well as experienced R&D professionals.